Dr. Reddy’s Laboratories Ltd ADR - Asset Resilience Ratio
Dr. Reddy’s Laboratories Ltd ADR (RDY) has an Asset Resilience Ratio of 12.88% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Dr. Reddy’s Laboratories Ltd ADR debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Dr. Reddy’s Laboratories Ltd ADR's Asset Resilience Ratio has changed over time. See RDY total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Dr. Reddy’s Laboratories Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RDY market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $9.91 Billion | 1.83% |
| Short-term Investments | $59.91 Billion | 11.05% |
| Total Liquid Assets | $69.81 Billion | 12.88% |
Asset Resilience Insights
- Moderate Liquidity: Dr. Reddy’s Laboratories Ltd ADR has 12.88% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Dr. Reddy’s Laboratories Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Dr. Reddy’s Laboratories Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Dr. Reddy’s Laboratories Ltd ADR (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Dr. Reddy’s Laboratories Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 9.28% | $45.76 Billion | $492.99 Billion | -10.58pp |
| 2024-03-31 | 19.86% | $76.96 Billion | $387.52 Billion | +1.55pp |
| 2023-03-31 | 18.31% | $58.95 Billion | $321.85 Billion | +8.21pp |
| 2022-03-31 | 10.10% | $29.59 Billion | $292.83 Billion | -6.03pp |
| 2021-03-31 | 16.14% | $586.04 Million | $3.63 Billion | +2.10pp |
| 2020-03-31 | 14.04% | $431.11 Million | $3.07 Billion | +4.00pp |
| 2019-03-31 | 10.04% | $22.64 Billion | $225.43 Billion | +1.47pp |
| 2018-03-31 | 8.57% | $19.34 Billion | $225.60 Billion | +0.92pp |
| 2017-03-31 | 7.65% | $16.82 Billion | $219.82 Billion | -9.22pp |
| 2016-03-31 | 16.87% | $35.03 Billion | $207.65 Billion | -0.72pp |
| 2015-03-31 | 17.59% | $34.26 Billion | $194.76 Billion | +2.85pp |
| 2014-03-31 | 14.74% | $25.08 Billion | $170.22 Billion | +2.82pp |
| 2013-03-31 | 11.91% | $169.63 Billion | $1.42 Trillion | +2.90pp |
| 2012-03-31 | 9.02% | $10.77 Billion | $119.48 Billion | +8.98pp |
| 2011-03-31 | 0.03% | $33.00 Million | $95.00 Billion | -5.16pp |
| 2010-03-31 | 5.19% | $4.17 Billion | $80.33 Billion | +4.56pp |
| 2009-03-31 | 0.63% | $530.00 Million | $83.79 Billion | -4.93pp |
| 2008-03-31 | 5.56% | $4.75 Billion | $85.45 Billion | +5.55pp |
| 2007-03-31 | 0.02% | $15.38 Million | $86.12 Billion | 0.00pp |
| 2006-03-31 | 0.02% | $14.70 Million | $68.77 Billion | -1.04pp |
| 2005-03-31 | 1.06% | $310.87 Million | $29.29 Billion | -8.47pp |
| 2004-03-31 | 9.53% | $2.54 Billion | $26.68 Billion | -28.32pp |
| 2003-03-31 | 37.85% | $8.71 Billion | $23.03 Billion | +37.85pp |
| 2002-03-31 | 0.00% | $516.00K | $18.95 Billion | 0.00pp |
| 2001-03-31 | 0.00% | $399.00K | $11.84 Billion | -2.47pp |
| 2000-03-31 | 2.47% | $3.84 Million | $155.57 Million | -- |
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more